Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
about
The role of day-to-day emotions, sleep, and social interactions in pediatric anxiety treatment.Pharmacotherapy of major depression in late life: what is the role of new agents?Specific depressive symptoms predict remission to aripiprazole augmentation in late-life treatment resistant depression.Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.A Machine Learning Approach to Identifying Placebo Responders in Late-Life Depression Trials.
P2860
Combining moderators to identify clinical profiles of patients who will, and will not, benefit from aripiprazole augmentation for treatment resistant late-life major depressive disorder.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Combining moderators to identi ...... ife major depressive disorder.
@ast
Combining moderators to identi ...... ife major depressive disorder.
@en
type
label
Combining moderators to identi ...... ife major depressive disorder.
@ast
Combining moderators to identi ...... ife major depressive disorder.
@en
prefLabel
Combining moderators to identi ...... ife major depressive disorder.
@ast
Combining moderators to identi ...... ife major depressive disorder.
@en
P2093
P2860
P50
P1476
Combining moderators to identi ...... ife major depressive disorder.
@en
P2093
Benoit H Mulsant
Daniel M Blumberger
Eric J Lenze
Francis E Lotrich
Jordan F Karp
Mary Amanda Dew
Meredith L Wallace
Meryl A Butters
Stephen F Smagula
P2860
P304
P356
10.1016/J.JPSYCHIRES.2016.07.005
P577
2016-07-07T00:00:00Z